1. Anti-infection
    Metabolic Enzyme/Protease
  2. HIV
    HIV Protease

Fosamprenavir Calcium Salt (Synonyms: GW433908G)

Cat. No.: HY-17431 Purity: 99.19%
Data Sheet SDS Handling Instructions

GW433908 is a phosphate ester prodrug of the antiretroviral protease inhibitor amprenavir, with improved solubility over the parent molecule and a potential for reduced pill burden on current dosing regimens; GW433908G is the calcium salt of the prodrug.

For research use only. We do not sell to patients.
Fosamprenavir Calcium Salt Chemical Structure

Fosamprenavir Calcium Salt Chemical Structure

CAS No. : 226700-81-8

Size Price Stock Quantity
1 mg $148 In-stock
5 mg $650 In-stock
10 mg $1190 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

GW433908 is a phosphate ester prodrug of the antiretroviral protease inhibitor amprenavir, with improved solubility over the parent molecule and a potential for reduced pill burden on current dosing regimens; GW433908G is the calcium salt of the prodrug. IC50 Value: Target: HIV Protease in vitro: There were no significant changes in buprenorphine or PI plasma levels and no significant changes in medication adverse effects or opioid withdrawal. Increased concentrations of the inactive metabolite buprenorphine-3-glucuronide suggested that darunavir-ritonavir and fosamprenavir-ritonavir induced glucuronidation of buprenorphine[1]. in vivo: Fosamprenavir-ritonavir administered with methadone did not alter plasma amprenavir pharmacokinetics compared with historical control data; nor did it alter the unbound R-methadone at 2 and 6 hours after methadone dosing. Pharmacodynamic indexes remained essentially unchanged after adding fosamprenavir-ritonavir to methadone [2]. After a high-fat meal compared with fasting, (1) the bioavailability of GW433908G suspension was decreased by 20% and Cmax by 41%, and (2) for GW433908G tablets, there was no influence on AUC(12% lower Cmax). After a low-fat meal compared with fasting, (1) there was bioequivalence for GW433908G tablets, but (2) bioavailability was decreased by 23% for amprenavir capsules (Cmax was also lower, by 46%) [3]. Clinical trial: Study of an Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects. Phase 2

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT01222611 Fundacion SEIMC-GESIDA|ViiV Healthcare Chronic HIV Infection|HCV Coinfection March 2011 Phase 4
NCT00240552 ViiV Healthcare|GlaxoSmithKline Infection, Human Immunodeficiency Virus July 2003 Phase 4
NCT00817765 Radboud University|GlaxoSmithKline HIV Infection|Fungal Infection January 2009 Phase 1
NCT00094523 ViiV Healthcare Infection, Human Immunodeficiency Virus I|HIV Infection December 2004 Phase 3
NCT01209065 ViiV Healthcare|GlaxoSmithKline Infections, Human Immunodeficiency Virus and Herpesviridae September 2010 Phase 1
NCT00296504 ViiV Healthcare|GlaxoSmithKline Infection, Human Immunodeficiency Virus November 2001 Phase 3
NCT00977301 Radboud University|GlaxoSmithKline HIV Infections November 2009 Phase 1
NCT01010399 Felizarta, Franco, M.D.|GlaxoSmithKline Hypertriglyceridemia|HIV Infection September 2009 Phase 4
NCT00363142 GlaxoSmithKline HIV Infection|Infection, Human Immunodeficiency Virus May 2006 Phase 3
NCT00481182 GlaxoSmithKline Healthy Subjects February 2005 Phase 1
NCT00450580 ViiV Healthcare|GlaxoSmithKline Infection, Human Immunodeficiency Virus I|HIV-1 Infection March 2007 Phase 3
NCT00040664 ViiV Healthcare HIV Infection July 2002 Phase 2
NCT00242216 The University of Texas Health Science Center, Houston HIV Infections May 2004 Phase 4
NCT01290211 ViiV Healthcare|Pfizer Healthy April 2011 Phase 1
NCT01140412 ViiV Healthcare|Pfizer Healthy July 2010 Phase 1
NCT00764465 Garden State Infectious Disease Associates, PA|GlaxoSmithKline Healthy October 2008 Phase 2
NCT00144833 GlaxoSmithKline HIV-1 March 2005 Phase 3
NCT00775125 Tibotec BVBA Hepatitis C|Telaprevir|HIV June 2008 Phase 1
NCT00614991 Garden State Infectious Disease Associates, PA|GlaxoSmithKline Healthy January 2008
NCT00802074 Garden State Infectious Disease Associates, PA|GlaxoSmithKline Healthy December 2008
NCT00043888 GlaxoSmithKline HIV Infections January 2002 Phase 3
NCT00122603 French National Agency for Research on AIDS and Viral Hepatitis|Bristol-Myers Squibb|GlaxoSmithKline|Hoffmann-La Roche HIV Infections December 2005 Phase 2
NCT00148785 Emory University HIV Infections July 2005 Phase 4
NCT00085943 GlaxoSmithKline HIV Infection|Infection, Human Immunodeficiency Virus May 2004 Phase 3
NCT00877591 University of California, San Francisco|State University of New York at Buffalo|University of Utah Opioid Dependency|HIV Infections April 2008 Phase 1
NCT00028366 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections
NCT00027339 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 2
View MoreCollapse
References
Molecular Weight

623.67

Formula

C₂₅H₃₄CaN₃O₉PS

CAS No.

226700-81-8

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

H2O: 0.25 mg/mL (Need ultrasonic and warming); DMSO: 1.8 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Fosamprenavir Calcium Salt
Cat. No.:
HY-17431
Quantity: